E.P.T. CERTAINTY 1-STEP PREGNANCY TEST
K061769 · Unipath , Ltd. · LCX · Jul 3, 2006 · Clinical Chemistry
Device Facts
| Record ID | K061769 |
| Device Name | E.P.T. CERTAINTY 1-STEP PREGNANCY TEST |
| Applicant | Unipath , Ltd. |
| Product Code | LCX · Clinical Chemistry |
| Decision Date | Jul 3, 2006 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 862.1155 |
| Device Class | Class 2 |
Intended Use
e.p.t Certainty® 1-Step Pregnancy Test is an over-the-counter urine hCG test which is intended for the detection of pregnancy. The test is indicated for use from four days before the expected period.
Device Story
e.p.t Certainty® 1-Step Pregnancy Test is a lateral flow immunoassay for qualitative detection of human chorionic gonadotropin (hCG) in urine. Device intended for home use by lay individuals. User applies urine sample to test device; hCG, if present, binds to labeled antibodies, migrating along membrane to capture zone, producing visible line indicating pregnancy. Results provide early detection of pregnancy. Device aids in clinical decision-making by confirming pregnancy status, allowing users to seek appropriate prenatal care.
Clinical Evidence
No clinical data provided; device relies on analytical performance characteristics typical of lateral flow hCG immunoassays.
Technological Characteristics
Lateral flow immunoassay; qualitative detection of hCG in urine; manual test format; non-electronic; no software; no external energy source.
Indications for Use
Indicated for over-the-counter detection of pregnancy in urine, starting four days before the expected period.
Regulatory Classification
Identification
A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.
Related Devices
- K032939 — EPT CERTAINTY PREGNANCY TEST · Unipath , Ltd. · Oct 20, 2003
- K040329 — MODIFICATION TO E.P.T. PREGNANCY TEST · Unipath , Ltd. · Mar 8, 2004
- K033658 — E.P.T. PREGNANCY TEST · Unipath , Ltd. · Jan 16, 2004
- K023699 — CLEARBLUE EASY EARLY RESULT PREGNANCY TEST · Unipath , Ltd. · Nov 27, 2002
- K050930 — E.P.T. CERTAINTY PREGNANCY TEST · Unipath , Ltd. · May 12, 2005
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Louise Roberts Regulatory Affairs Manager Unipath Ltd. Priory Business Park Bedford MK44 3UP United Kingdom
JUL - 3 2006
Re: k061769 Trade/Device Name: e.p.t Certainty® 1-Step Pregnancy Test Regulation Number: 21 CFR§862.1155 Regulation Name: Human chorionic gonadotropin (HCG) test system Regulatory Class: Class II Product Code: LCX Dated: June 21, 2006 Received: June 23, 2006
Dear Ms. Roberts:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device, can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act`s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{1}------------------------------------------------
## Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to 1 logally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please not the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tolloffred number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Albert Gutt
Alberto Guticarez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## Indications for Use
510(k) Number (if known): K06176
Device Name: e.p.t Certainty® 1-Step Pregnancy Test
Indications For Use:
e.p.t Certainty® 1-Step Pregnancy Test is an over-the-counter urine hCG test which is intended for the detection of pregnancy. The test is indicated for use from four days before the expected period.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use X (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
AC
K06 1769
Page I of 1